22
Views
16
CrossRef citations to date
0
Altmetric
Oncology

Histopathological and immunohistochemical study of malignant transformation of oral leukoplakia, with special reference to apoptosis-related gene products and proliferative activity

, &
Pages 767-775 | Received 04 Sep 2002, Accepted 12 Dec 2002, Published online: 21 Nov 2014

References

  • Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. International histological classification of tumours: histological typing of cancer and precancer of the oral mucosa. Geneva, Switzerland: World Health Organisa-tion; 1997.
  • Bouquot JE. Reviewing oral leukoplakia: clinical con-cepts for the 1990s. J Am Dent Assoc 1991; 122: 80–2.
  • Lind PO. Malignant transformation in oral leukoplakia. Scand J Dent Res 1987; 95: 449–55.
  • Hogewind WFC, van der Kwast WAM, van der Waal I. Oral leukoplakia, with emphasis on malignant transfor-mation: a follow-up study of 46 patients. J Craniomax-illofac Surg 1989; 17: 128–33.
  • Pindborg JJ, Renstrup G, Joist 0, Roed-Petersen B. Studies in oral leukoplakia: a preliminary report on the period of prevalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients. J Am Dent Assoc 1968; 76: 767–71.
  • Takagi M, Sakota Y, Ishikawa G. Histopathologic study of the squamous cell carcinoma of the oral mucosa. 1. Relationship between leukoplakia and invasive carci-noma. Kokubyo Gakkai Zasshi 1975; 42: 364–72.
  • Amagasa T, Totsuka M, Masuo K, Nagai J, Shimizu M, et al. Study on oral leukoplakia from the viewpoint of its clinical type, treatment and prognosis. J Oral Maxillofac Surg 1978; 24: 243–52.
  • Washizu K, Ono I, Ebihara S, Saito H, Majima K, et al. A study of oral precancerous lesions. Jpn J Cancer Clin 1981; 27: 942–7.
  • Inoue A, Sakamoto A, Uchida M, Kamata S. Malignant progression of oral leukoplakia-a long-term follow-up study. Jpn J Clin Oncol 1985; 20: 18–24.
  • Reed JC. Bc1-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1 6.
  • Norris DA. Differential control of cell death in the skin. Arch Dermatol 1995; 131: 945–8.
  • Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, et al. Bc1-x, a bc1-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597–608.
  • Oltvai ZN, Milliman CL, Korsmeyer SJ. Bc1-2 hetero-dimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–19.
  • Muraki Y, Yoshioka C, Fukuda J, Haneji T. Immuno-histochemistry of Fas antigen •detection of Fas antigen in oral leukoplakia, lichen planus, and squamous cell carcinoma. J Oral Maxillofac Surg 1997; 43: 693–8.
  • Dekker NP, Lozada-Nur F, Lagenaur LA, MacPhail LA, Bloom CY, et al. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med 1997; 26: 170–5.
  • Birchall MA, Winterford CM, Allan DJ, Harmon By. Apoptosis in normal epithelium, premalignant and malignant lesions of the oropharynx and oral cavity: a preliminary study. Eur J Cancer 1995; 31B: 380–3.
  • Birchall MA, Schock E, Harmon BY, Gob& G. Apop-tosis, mitosis, PCNA and bc1-2 in normal, leukoplakic and malignant epithelia of the human oral cavity:prospective, in vivo study. Oral Oncol 1997; 33: 419–25.
  • Muraki Y, Yoshioka C, Fukuda J, Haneji T, Kobayashi N. Immunohistochemical detection of Fas antigen in oral epithelia. J Oral Pathol Med 1997; 26: 57–62.
  • Chrysomali E, Greenspan JS, Dekker N, Greenspan D, Regezi JA. Apoptosis-associated proteins in oral hairy leukoplakia. Oral Dis 1996; 2: 279–84.
  • Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493 501.
  • Burkhardt A. Advanced methods in the evaluation of premalignant lesions and carcinomas of the oral mu-cosa. J Oral Pathol Med 1985; 14: 751–78.
  • Verheijen R, Kuijpers HJH, Schlingeman RO, Boehmer ALM, van Driel R, et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. 1. Intracellular localization during interphase. J Cell Sci 1989; 92: 123–30.
  • Liu SC, Klein-Szanto AJP. Markers of proliferation in normal and leukoplakic oral epithelia. Oral Oncol 2000; 36: 145–51.
  • Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345–7.
  • Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847–9.
  • Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, et al. Thymocyte apoptosis induced by p53-depen-dent and independent pathways. Nature 1993; 362: 849–52.
  • Lane DP. p53, guardian of the genome. Nature 1992; 358: 15–6.
  • Takahashi R, Inagaki T. p53-induced apoptosis. Exp Med 1995; 13: 42–4.
  • Dimitrakakis C, Kymionis G, Diakomanolis E, Papa-spyrou I, Rodolakis A, et al. The possible role of p53 and bc1-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol 2000; 77: 129–36.
  • Wang LD, Zhou Q, Yang WC, Yang CS. Apoptosis and cell proliferation in esophageal precancerous and can-cerous lesions: study of a high-risk population in Northern China. Anticancer Res 1999; 19: 369–74.
  • Morsi HM, Leers MPG, Radespiel-Tröger M, Björklund V, Kabarity HE, et al. Apoptosis, bc1-2 expression, and proliferation in benign and malignant endometrial epithelium: an approach using multiparameter flow cytometry. Gynecol Oncol 2000; 77: 11–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.